Table 3.
In vitro activity of ceftazidime/avibactam/aztreonam combination against carbapenem resistant E. coli
| S. No | Sample ID | Zone diameter in millimeter | Interpretation Synergy/No synergy | Genes detected | ||
|---|---|---|---|---|---|---|
|
| ||||||
| Ceftazidime/Avibactam | Aztreonam | Ceftazidime/Avibactam/Aztreonam | ||||
| 1 | Pus | R (9 mm) | I (19 mm) | 19 mm | Synergy negative | NDM |
| 2 | Pus | R (6 mm) | R (6 mm) | 6 mm | Synergy negative | NDM |
| 3 | Urine | S (24 mm) | R (6 mm) | 19 mm | Synergy negative | NDM |
| 4 | Urine | R (6 mm) | R (6 mm) | 6 mm | Synergy negative | NDM |
| 5 | Urine | R (14 mm) | R (16 mm) | 19 mm | Synergy positive | NDM&OXA 48 |
| 6 | Urine | R (20 mm) | R (6 mm) | 20 mm | Synergy positive | NDM |
| 7 | Urine | R (14 mm) | R (6 mm) | 20 mm | Synergy positive | NDM&OXA 48 |
| 8 | Pus | R (6 mm) | R (11 mm) | 23 mm | Synergy positive | NDM |
| 9 | Pus | R (14 mm) | R (6 mm) | 17 mm | Synergy positive | NDM |
| 10 | Urine | R (6 mm) | R (6 mm) | 16 mm | Synergy positive | NDM |
| 11 | Urine | R (16 mm) | R (6 mm) | 20 mm | Synergy positive | NDM |
| 12 | Pus | R (14 mm) | R (6 mm) | 17 mm | Synergy positive | NDM &VIM |
| 13 | Pus | R (12 mm) | R (10 mm) | 19 mm | Synergy positive | NDM |
| 14 | Urine | R (16 mm) | R (6 mm) | 21 mm | Synergy positive | NDM&OXA 48 |
| 15 | Urine | R (12 mm) | R (13 mm) | 22 mm | Synergy positive | NDM |
| 16 | Urine | R (12 mm) | R (16 mm) | 12 mm | Synergy negative | NDM |
| 17 | Urine | R (11 mm) | R (12 mm) | 13 mm | Synergy positive | NDM |
| 18 | Urine | R (14 mm) | R (6 mm) | 18 mm | Synergy positive | NDM&VIM |
| 19 | Urine | R (14 mm) | R (6 mm) | 14 mm | Synergy positive | NDM |
| 20 | Urine | R (14 mm) | R (6 mm) | 17 mm | Synergy positive | NDM |
| 21 | Urine | R (15 mm) | R (6 mm) | 15 mm | Synergy positive | NDM |
| 22 | Urine | R (15 mm) | I (18 mm) | 10 mm | Synergy negative | NDM |
| 23 | Urine | R (10 mm) | R (10 mm) | 15 mm | Synergy positive | NDM |